Dr Dreyling on Frontline BTK Inhibitor–Based Treatment in Mantle Cell Lymphoma

EP. 1: Dr Dreyling on the Expanding Role of BTK Inhibitors in the Treatment of MCL

April 4th 2025

Martin Dreyling, MD, discusses the expanding role of BTK inhibitors in the treatment of mantle cell lymphoma.

EP. 2: Dr Dreyling on Investigating ASCT Plus Ibrutinib and R-CHOP in Younger, Fit Patients With MCL

May 19th 2025

Martin Dreyling, MD, discusses the patient population studied in the TRIANGLE trial of ASCT plus ibrutinib-containing therapy in younger patients with MCL.

EP. 3: Dr Dreyling on the Efficacy of Frontline Acalabrutinib Plus BR in High-Risk MCL

August 21st 2025

Martin Dreyling, MD, PhD, discusses the efficacy of first-line acalabrutinib plus BR in high-risk patients with mantle cell lymphoma.

EP. 4: Dr Dreyling on the Role of BTK Inhibitors in Frontline MCL

September 26th 2025

Martin Dreyling, MD, PhD, discusses the use of BTK inhibitors in frontline mantle cell lymphoma.

EP. 5: Dr Dreyling on the Rationale for Adding Acalabrutinib to BR in High-Risk MCL

October 8th 2025

Martin Dreyling, MD, discusses why adding acalabrutinib to bendamustine plus rituximab may benefit patients with pretreated, high-risk MCL.

EP. 6: Dr Dreyling on Prior Findings From the ECHO Trial of Acalabrutinib Plus BR in Pretreated MCL

October 15th 2025

Martin Dreyling, MD, discusses prior findings and potential implications of the phase 3 ECHO trial of acalabrutinib plus BR in pretreated MCL.

EP. 7: Dr Dreyling on the Recommended Use of Acalabrutinib Plus BR in Pretreated MCL

October 22nd 2025

Martin Dreyling, MD, provides recommendations for use of acalabrutinib plus BR in pretreated MCL based on updated data from the phase 3 ECHO trial.

EP. 8: Dr Dreyling on the Evolving Role of BTK Inhibitors in MCL Management

October 29th 2025

Martin Dreyling, MD, speculated on the future role of BTK inhibitors either alone or in non-cytotoxic chemotherapy combinations for patients with MCL.